Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Product Approvals
|
Clinical Trials
|
Product Filings
|
Product Safety
|
Preclinical
|
Product Delays
|
Research & Development - Preclinical
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
Europe to give €12 million for influenza antiviral projects
12 March 2010
The European Commission will provide €12 million in funding for two new research projects which will develop novel influenza treatments, including against both (A) H1N1 pandemic influenza and (A) H5N1 avian flu. Speaking at an EU influenza meeting ...
Interview: natural toxin just the tonic for CK Life Sciences
08 March 2010
Gourmets in Japan may be more accustomed to eating at least the safer parts of it, but the humble puffer fish has also given CK Life Sciences (CKLS) the potent neurotoxin upon which its lead drug development project is based. The Hong Kong venture ...
Medivation/Pfizer's disappointing Dimebon data sends Alzheimer's hopes, and shares, crashing
04 March 2010
Medivation / Pfizer 's experimental Alzheimer's disease drug Dimebon (latrepirdine), failed to differentiate from placebo and met none of its endpoints, show top-line results of the first Phase III efficacy trial, dashing the hopes of doctors, ...
US FDA allows Synta to resume development of anticancer elesclomol
03 March 2010
Synta Pharmaceuticals has received the go-ahead from the US FDA to resume development of its novel anticancer elesclomol, an oxidative stress inducer whose closely watched Phase III trial in metastatic melanoma was suspended last year on safety ...
Interview: Rexbio sets sights on novel approach to pancreatic cancer
08 February 2010
The South Korean bioventure Rexbio is looking to develop a novel approach to the treatment and diagnosis of one of the most deadly forms of cancer by targeting a gene found to be closely linked to the malignancy. The small, privately held company is ...
 
Market Insight - Fear gives way to prudence as VCs eye return of bull biotech market
19 February 2010
2009 was a bad year for investment in the biotech sector, with venture capital funds fleeing to safer havens and many small firms struggling to get enough financing to keep their R&D projects afloat. ...
Market Insight - Microdosing reaching a tipping point?
05 February 2010
Advocates of microdosing, a technique that involves testing very small doses of products in humans, think it will improve the efficiency of drug development by flagging at an early stage those ...
Market Insight - How the IMI is reinvigorating European pharma research
19 January 2010
The Innovative Medicines Initiative (IMI) is a public-private partnership which aims to bolster Europe's competitive edge in pharmaceutical research and improve the mechanisms for bringing new ...
 
Cellectis: Partner search is on for meganuclease technology
25 September 2009
The French genome engineering company Cellectis is generating good publicity for its meganuclease technology following its recent deal with Servier for the use of its ∏10 research kit. Scrip's Sita ...
Antibodies emerge as key focus for Kyowa Kirin
05 June 2009
Kyowa Hakko Kirin (KHK) is applying the technologies brought together by the merger of Kyowa Hakko and Kirin Pharma to an expanding pipeline of antibody products. The hope was that the merger, ...
 
Commentary: Pharma's future is virtual,say Kate Moss and Dr Steve Arlington of PricewaterhouseCoopers
09 July 2008
In its latest Pharma 2020: Virtual R&D report on the future of the sector, PricewaterhouseCoopers argues that incremental changes are no longer enough. Companies will need to decide what they want to ...
 
Drug discovery paradigms: past, present, future – a centennial symposium of the American Society for Pharmacology and Experimental Therapeutics
01 September 2008
Background: The American Society for Pharmacology and Experimental Therapeutics (ASPET) celebrated its centennial during the April 2008 Experimental Biology meeting held in San Diego, CA, USA. ...
Selective dopamine D3 receptor antagonists. A decade of progress: 1997 – 2007
01 August 2008
Background: A growing number of patent applications on dopamine (DA) D 3 receptors have been filed over the last 10 years. The increased interest in this target correlates with evidence that ...
Trans-sodium crocetinate for treating hypoxia/ischemia
01 June 2008
Background: Trans-sodium crocetinate (TSC) is a novel compound that offers promise as a treatment for conditions caused by hypoxia or ischemia. TSC was originally developed at the University of ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm